Health Promotion in Asia‐Pacific: Evidence Base for Good Practice?
Health Promotion Journal of Australia · 2025
DOI: 10.1002/hpja.70107 ↗Kurz gefasst
Editorial in der Zeitschrift Health Promotion Journal of Australia, 2025. Verfasst von Vivian Lin. Beteiligte Einrichtung: LaTrobe University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Health Promotion, Evidence-Based Practice.
Abstract (Originalsprache)
The practice of health promotion in the Asia‐Pacific Region has evolved from health education to a settings‐based approach. Increasingly, health promotion approaches are being applied to an ever wider range of health issues. Despite substantial developments across many countries, the evidence base for good practice in the Region has been slow to develop. This reflects both resourcing limitations as well as low connectivity between researchers, practitioners and policy‐makers. The vastly different cultures, languages, population groups and geographies call for greater understanding of the context‐specific nature of health promotion interventions and offer tremendous opportunity for further knowledge generation and dissemination. A more robust evidence base, focused on current and emerging challenges, will serve all stakeholders well in garnering the necessary funding and resources for well‐designed interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- LaTrobe University, Melbourne, Victoria, Australia.
- University of Hong Kong, Hong Kong, Hong Kong.
Zitieren
APA
Lin, V. (2025). Health Promotion in Asia‐Pacific: Evidence Base for Good Practice?. Health Promotion Journal of Australia. https://doi.org/10.1002/hpja.70107
Vancouver
Lin V. Health Promotion in Asia‐Pacific: Evidence Base for Good Practice?. Health Promotion Journal of Australia. 2025. doi:10.1002/hpja.70107
BibTeX
@article{Lin2025,
author = {Lin, Vivian},
title = {Health Promotion in Asia‐Pacific: Evidence Base for Good Practice?},
journal = {Health Promotion Journal of Australia},
year = {2025},
doi = {10.1002/hpja.70107}
}
EUVIMED